Pacritinib for VEXAS syndrome
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether the drug pacritinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition that causes inflammation in various parts of the body. It may be a new treatment option for those who still have inflammation despite taking steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed mutation in the UBA1 gene linked to VEXAS syndrome (your doctor can check this).
- You have had inflammation in at least one organ system (like skin, joints, eyes, or lungs) due to VEXAS within the past 6 months.
- You are currently on a stable dose of prednisone or prednisolone (15-45 mg per day) at the start of the trial.
- You are generally able to care for yourself (Karnofsky score of at least 50%).
- You have adequate kidney, liver, and blood cell counts as determined by standard lab tests.
- You agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
This study tests whether the drug momelotinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition. Participants will keep taking their usual steroids and may receive momelotinib or a placebo to see if it helps control the disease.
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
This study aims to find out how common VEXAS syndrome is and how it looks in people over 50 who have unexplained inflammation or blood issues. It helps doctors better recognize and diagnose this rare condition.
This study looks at how VEXAS syndrome affects your daily life and finances. It aims to understand the challenges you face so doctors can better support you.
This trial tests a drug called momelotinib for people with VEXAS syndrome, a rare inflammatory condition. The goal is to see if momelotinib can reduce symptoms and the need for steroids.
Hear when a new VEXAS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.